Home · Mappa; Xagena. Chi siamo · News (IT) · News (EN) · MedicinaNews · MedicineNews · Partner. Cardiologia. News · Farmaci · Focus. Oncologia. News · Farmaci · Focus · Immunoterapia. OncoHub. OncoDermatologia · OncoEmatologia · OncoGastroenterologia · OncoGeriatria · OncoGinecologia · OncoNeurologia …

Pharmacogenetics could reduce the incidence of adverse reactions and optimize treatments. Researchers, at Washington University School of Medicine in St. Louis and the St. Louis College of Pharmacy, found that 29 percent of patients seen at local primary-care offices had taken at least one .

Catalase enzyme prolongs mouse lifespan. A research, led by scientists from University of Washington in Seattle, has found that mice genetically engineered to produce high levels of a human antioxidant enzyme lived longer than normal mice. T ..

FDA Advisory Panel recommends Tarceva approval for pancreatic cancer. The FDA’s Oncologic Drug Advisory Committee ( ODAC ) voted 10 to 3 in favor of recommending approval of Tarceva ( Erlotinib ) in combination with Gemcitabine for the treatment of advanced pancreatic c .

FDA warns against abuse of Dextromethorphan. FDA ( Food and Drug Administration ) is concerned about the abuse of Dextromethorphan ( DXM ), a synthetically produced ingredient found in many over-the-counter ( OTC ) cough and cold remedies. T ..

Differentiated thyroid cancer: Lenvatinib, an orally administered multiple receptor tyrosine kinase inhibitor. Lenvatinib ( Lenvima ) is an orally administered multiple receptor tyrosine kinase ( RTK ) inhibitor with a novel binding mode that selectively inhibits the kinase activities of vascular endothelial g .